Fred Powell (Insider Trades), vice president of Celator Pharmaceuticals Inc. (CPXX), bought 13,700 shares of the company on Oct. 5. The average price per share was $1.75 for a total transaction cost of $24,386. Celator Pharmaceuticals is a biopharmaceutical company that develops products to improve patient outcomes in cancer. It has a market cap of $58.98 million.
The volume of Celator insider trades increased from 5,500 shares in 2013 to 25,900 shares from January to September of this year. The number of insider trades doubled from 2013 to 2014, and the volume of insider trades increased seven-fold during the same period of time. Powell made four insider buys with the company totaling 24,700 shares since December 2013; his earliest transaction decreased about 50% in price since the purchase. Valence Life Sciences GP (Insider Trades) bought 12,200 shares of Celator on Oct. 1 at an average price of $1.64 per share. Celator's month end price decreased about 60% in the two years following September 2013, indirectly correlating with the number and volume of insider buys during the same time period. 
For more information about insider transactions with Celator, click here.
Celator reported a net loss of $4.982 million, or 15 cents per share, in the second quarter of 2015. Net income decreased by 18 cents per share from the year-ago quarter. On Sept. 24, Celator announced their successful research and development efforts to apply the CombiPlex technology platform to optimize the efficacy of anticancer drug combinations incorporating molecularly targeted agents (MTAs). Another benefit observed during this study was the versatility and modular nature of the nanoparticle technology. Lawrence Mayer, Celator president and chief scientific officer, commented that the company “achieved this milestone on time, and believe these data may help Celator establish collaborative R&D programs with pharma partners.” The company also started a clinical study of CPX-351 in Acute Myeloid Leukemia at high risk for induction mortality on July 14. Phase 2 studies with CPX-351 observed improved efficacy and reduced early mortality in the majority of patients.
For more stock trades of gurus in real time, visit GuruFocus’ Real Time Picks, a Premium Feature. Not a Premium Member of GuruFocus? Try it free for 7 days here.
